Jun 18, 2013 Medtronic Saga: Corrupt Science, Belated Warning - YCharts
Jun 18, 2013 North America Injectable Drug Delivery Market - 2013 Report - M2
Jun 18, 2013 The FDA Might Pull This Drug From the Market (and Why It Doesn`t Matter) - TheMotleyFool
Jun 18, 2013 Transition Therapeutics Inc reports exercise of rights to TT-401 by Eli Lilly and Company - M2
Jun 18, 2013 Why MannKind Is Poised to Pull Back - TheMotleyFool
Jun 17, 2013 Bullish Moving Average Cross by Eli Lilly (LLY) - Financial News Network Online - Moving Average Crossovers
Jun 17, 2013 Eli Lilly (LLY) Approaches New Upside Target of $52.80 - Financial News Network Online - Pivot Alerts
Jun 17, 2013 Eli Lilly to Take Over Development of Diabetes Drug - TheMotleyFool
Jun 17, 2013 Global Insulin Delivery Devices Market Forecast to 2017 - M2
Jun 17, 2013 Lilly Diabetes, Kris Freeman Kick off Summer with 9th Annual Diabetes Summer Camp Tour - Pr Newswire
Jun 17, 2013 New Data Showed LIVALOA? (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1c Levels in HIV-infected Adults with Dyslipidemia - Pr Newswire
Jun 17, 2013 Pharma Stocks: Court Ruling`s Real Meaning - YCharts
Jun 17, 2013 Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly - Cnw Group
Jun 17, 2013 Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly - Pr Newswire
Jun 16, 2013 Did This Study Just Change the Game for Alzheimer`s? - TheMotleyFool
Jun 15, 2013 Another Alzheimer`s Disease Failure - TheMotleyFool
Jun 15, 2013 This Week in Biotech - TheMotleyFool
Jun 14, 2013 Cramer`s 6 Stocks in 60 Seconds: GME LLY RBCN AXP HRL CLH (Update 1) - TheStreet.com
Jun 14, 2013 Cramer`s 6 Stocks in 60 Seconds: GME LLY RBCN AXP HRL CLH - TheStreet.com
Jun 14, 2013 Eli Lilly's Phase III lung cancer trial fails to meet primary endpoint - Datamonitor
Jun 14, 2013 Lilly announces voluntary cessation of Phase II study for LY2886721 - M2
Jun 14, 2013 Lilly to Present Late-Stage Pipeline Molecules at the 73rd American Diabetes Association Scientific Sessions - Close-Up Media
Jun 13, 2013 A Peek Into The Market Before The Trading Starts - Benzinga
Jun 13, 2013 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies - Pr Newswire
Jun 13, 2013 Cancer Diagnostics Partnering Terms and Agreements - M2
Jun 13, 2013 Eli Lilly Makes a Move: Down 1.3% - Financial News Network Online - Market Movers
Jun 13, 2013 Is This Healthcare Company a Strong Investment? - TheMotleyFool
Jun 13, 2013 Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease - Pr Newswire
Jun 13, 2013 Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis - Pr Newswire
Jun 13, 2013 Lilly, Incyte Announce Baricitinib Efficacy and Safety Data from Phase 2b JADA Study in Patients with Rheumatoid Arthritis - Benzinga
Jun 13, 2013 Ovarian Cancer Drug Half Way There - TheMotleyFool
Jun 12, 2013 Eli Lilly (LLY) Trading Near $51.47 Support Level - Freshbrewedmedia
Jun 12, 2013 Infectives Partnering Terms and Agreements Report Contains Over 2,000 Links to Online Copies of Actual Infectives Deals and Contract Document - M2
Jun 12, 2013 Musculoskeletal Partnering Terms and Agreements - 2013 Contains Over 1,500 Links to Online Copies of Actual Musculoskeletal Deals - M2
Jun 12, 2013 Perrigo files ANDA with FDA for generic treatment of low testosterone - Datamonitor
Jun 12, 2013 Pipeline vs. Expiring Patents: Eli Lilly???s Future - YCharts
Jun 12, 2013 Research Study Results Bring Hope for Combating Debilitating Diseases - Research Report on Johnson & Johnson, AbbVie, Lilly, Novartis and GlaxoSmithKline - Pr Newswire
Jun 11, 2013 Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific SessionsA? - Pr Newswire
Jun 11, 2013 Eli Lilly (LLY) Breaks Through Support at $52.25 - Comtex Smartrend(R)
Jun 11, 2013 Eli Lilly (LLY) Breaks Through Support at $52.25 - Financial News Network Online - Pivot Alerts
Jun 11, 2013 Hungary Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2018 - M2
Jun 11, 2013 Is Pfizer a Buy? - TheMotleyFool
Jun 11, 2013 Lilly to Highlight Late-Stage Pipeline Molecules at the 73rd American Diabetes Association Scientific SessionsA? - Pr Newswire
Jun 11, 2013 Parexel Trying To Clear Three-Weeks-Tight Buy Point - Investors Business Daily
Jun 10, 2013 Critical Alerts For Amazon.com, Eli Lilly, GNC Holdings, AngloGold Ashanti, and Rosetta Resources Released By InvestorsObserver - Pr Newswire
Jun 10, 2013 Eli Lilly announces encouraging data from osteoporosis study - Datamonitor
Jun 8, 2013 Billionaire Stanley Druckenmiller`s Big 5 - TheMotleyFool
Jun 8, 2013 Why You Should Care About This Diabetes Drug Saga - TheMotleyFool
Jun 7, 2013 Big Things Are Happening at This Pharmaceutical Company - TheMotleyFool
Jun 7, 2013 Billionaire Jim Simons` Buy Ups - TheMotleyFool
Jun 7, 2013 Buyers Accumulate Shares of Eli Lilly, Up 1.8% - Financial News Network Online - Market Movers
Jun 7, 2013 Eli Lilly (LLY) Breaks Through Resistance at $52.57 - Financial News Network Online - Pivot Alerts
Jun 7, 2013 Malignant Glioma - Pipeline Review, H1 2013 Reviews Key Players Involved in the Therapeutic Development - M2
Jun 6, 2013 ???Evergreening??? Patent-Expired Drugs: Pharma Tactic - YCharts
Jun 6, 2013 Drug Company Profits Set to Increase from Additions to DSM-5 (LLY, NVS, PFE) - Benzinga
Jun 6, 2013 Drug Company Profits Set to Increase from Additions to DSM-5 - Benzinga
Jun 6, 2013 Global Cancer Cachexia Report - Pipeline Review, H1 2013 Edition - M2
Jun 6, 2013 Pfizer`s Big Chance - TheMotleyFool
Jun 6, 2013 Potential Eli Lilly (LLY) Trade Has $50.12 Breakeven - Freshbrewedmedia
Jun 6, 2013 Sarissa`s Stake in VIVUS Points to Renewed Interest in the Company - TheMotleyFool
Jun 5, 2013 Eli Lilly Reports Pronounce Study Results - Close-Up Media
Jun 5, 2013 Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited - M2
Jun 5, 2013 Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2013 - M2
Jun 5, 2013 Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer - M2
Jun 5, 2013 Profiting from Diabetes Expenses - TheMotleyFool
Jun 5, 2013 Skin Cancer - Pipeline Review, H1 2013 Features Key Players Involved - M2
Jun 5, 2013 StockCall Pre-Market Review on BMY, LLY, ENDP, and AGN - Accesswire
Jun 5, 2013 World Diabetes Drug Market Prospects Examined in Topical Visiongain Report Now Available at MarketPublishers.com - Businesswire
Jun 4, 2013 American Diabetes Association and Lilly Announce Creation of ResearchAwards - Marketwire
Jun 4, 2013 Analyst Rating In Review: Eli Lilly Sold Off 1.8% Since Upgraded 7 Days Ago (LLY) - Financial News Network Online - News Corner
Jun 4, 2013 Eli Lilly Set to Possibly Rebound After Yesterday's Selloff of 1.19% - Comtex Smartrend(R)
Jun 4, 2013 Eli Lilly and Co.; Withdrawal of Approval of a New Drug Application for ORAFLEX - Federal Register
Jun 4, 2013 Pharma Sales Reps Increasingly Unwelcome - YCharts
Jun 4, 2013 Synta Pharmaceuticals: A Promising Biotech Stock for 2013 - TheMotleyFool
Jun 4, 2013 Watch for Eli Lilly to Potentially Rebound After Falling 1.19% Yesterday - Comtex Smartrend(R)
Jun 3, 2013 Actonel (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Aprela (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 BA-058 (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Corgenix collaborates with Eli Lilly to develop oncology diagnostic technology - Datamonitor
Jun 3, 2013 Eli Lilly sponsors MDLinx Oncology Articles mobile app - M2
Jun 3, 2013 Evista (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Forteo (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Ostora (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 PRONOUNCE Study Does Not Achieve Primary Superiority Endpoint for ALIMTAA? (pemetrexed for injection), Similar PFS and OS Results Were Observed Between the Two Drug and the Three Drug Regimens in the Treatment of NSCLC - Pr Newswire
Jun 3, 2013 PTH(1-31)NH2 (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Protelos (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Recalbon/Bonoteo (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
Jun 3, 2013 Reclast (Osteoporosis) - Forecast and Market Analysis to 2022 - M2
